BRIEF published on 11/05/2024 at 10:12, 1 year 10 months ago Leadership Transition at PharmaSGP Holding SE: Peter Gerckens to Succeed Natalie Weigand as CEO Company Growth OTC Pharmaceuticals Peter Gerckens Natalie Weigand PharmaSGP Leadership Change
PRESS RELEASE published on 11/05/2024 at 10:07, 1 year 10 months ago CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025 PharmaSGP Holding SE announces CEO change with Peter Gerckens succeeding Natalie Weigand on January 1, 2025. Smooth transition planned for internal succession Succession Plan CEO Change PharmaSGP Holding SE Peter Gerckens Natalie Weigand
BRIEF published on 11/05/2024 at 10:07, 1 year 10 months ago Leadership Change at PharmaSGP Holding SE: Peter Gerckens Appointed CEO Leadership Transition CEO Change PharmaSGP Holding SE Peter Gerckens Natalie Weigand
PRESS RELEASE published on 11/05/2024 at 10:02, 1 year 10 months ago EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer PharmaSGP Holding SE appoints Peter Gerckens as new CEO, succeeding Natalie Weigand. Gerckens, currently CCO, will assume the CEO position on January 1, 2025 Supervisory Board PharmaSGP Holding SE CEO Succession Peter Gerckens Natalie Weigand
BRIEF published on 10/01/2024 at 08:20, 1 year 11 months ago PharmaSGP Holding SE Acquires 477,701 Shares Through Repurchase Offer Share Buyback Treasury Shares Capital Reduction PharmaSGP Repurchase Offer
PRESS RELEASE published on 10/01/2024 at 08:15, 1 year 11 months ago PharmaSGP Holding SE has purchased 477,701 own shares through its public share repurchase offer PharmaSGP Holding SE has purchased 477,701 own shares through public share repurchase offer. The company's acceptance ratio is approximately 80.37% Share Buyback Treasury Shares Public Offer PharmaSGP Holding Acceptance Ratio
BRIEF published on 09/12/2024 at 08:20, 2 years ago PharmaSGP Continues Dynamic Growth Path in First Half of 2024 Revenue Growth International Expansion PharmaSGP OTC Pharmaceuticals 2024 Financials
BRIEF published on 09/12/2024 at 08:15, 2 years ago PharmaSGP Holding SE Announces Share Repurchase Program Share Repurchase Acceptance Period PharmaSGP Holding SE 594,405 Shares EUR 21.45
PRESS RELEASE published on 09/12/2024 at 08:15, 2 years ago PharmaSGP continues dynamic growth path in the first half of 2024 PharmaSGP Holding SE reports dynamic growth with half-year revenues reaching €58.4 million, up 17.4% from last year. Management expects full-year revenues to range from €107.0m to €112.0m Revenues Germany Growth Internationalization PharmaSGP
PRESS RELEASE published on 09/12/2024 at 08:10, 2 years ago EQS-Adhoc: PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares PharmaSGP Holding SE announces public share repurchase offer to buy back own shares for up to 594,405 shares, with acceptance period from September 13 to 26, 2024 Acceptance Period 2024 PharmaSGP Holding SE 594,405 Shares Share Repurchase Offer
Published on 09/18/2026 at 14:30, 2 hours 4 minutes ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/18/2026 at 13:30, 3 hours 4 minutes ago Alset AI Provides Shareholder Update, Announces Updated Investor Presentation and Appoints Mitchell Jackman as Chief Financial Officer
Published on 09/18/2026 at 06:30, 10 hours 4 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/18/2026 at 00:55, 15 hours 39 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 16:15, 19 minutes ago Hong Kong’s Chief Executive takes to the airwaves to discuss his strategic vision for development under the city’s First Five-Year Plan
Published on 09/17/2026 at 17:40, 22 hours 54 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 22 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 2 days 9 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
